Bausch Health extends its tender offer for Durect.
Written by Emily J. Thompson, Senior Investment Analyst
Tender Offer Announcement: Bausch Health Companies and DURECT Corporation announced an extension of the tender offer to acquire all outstanding shares of DURECT for $1.75 per share in cash.
Financial Details: The upfront consideration for the acquisition is approximately $63 million, with potential additional milestone payments of up to $350 million based on sales performance.
Extension of Expiration Date: The expiration date for the tender offer has been extended from September 9, 2025, to September 10, 2025, at 5:00 p.m. New York City time.
No Action Required for Shareholders: Shareholders who have already tendered their shares do not need to take any further action due to this extension.
Analyst Views on BHC
Wall Street analysts forecast BHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHC is 8.50 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 7.260
Low
7.00
Averages
8.50
High
10.00
Current: 7.260
Low
7.00
Averages
8.50
High
10.00
About BHC
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
